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Severe, acute graft versus host disease (aGvHD) contributes
signiﬁcantly to morbidity and mortality after allogeneic hemato-
poietic stem cell transplantation (allo-HSCT). Diagnosis of GvHD
is mainly based on clinical features and tissue biopsies, a non
invasive, unbiased laboratory test for GvHD diagnosis does not
exist. To establish such a test, capillary electrophoresis coupled
online with mass spectrometry (CE-MS) was applied to a train-
ingsset consiting of 13 urine samples from 10 allo-HSCT patients
with aGvHD  grade II and 50 urine samples of 23 patients
without GvHD.
Thirty one potential GvHD-speciﬁc polypeptides were chosen
out of 300 differenztially excreted peptides, based on the high
discriminatory values allowing differentiation of patients with
aGvHD from those with no GvHD. This pattern was then used to
characterize urine samples from 141 patients that were collected
prospectively and blinded. The aGvHD speciﬁc model allowed
correct classiﬁcation of 13/13 (sensitivity 100.0 % [95 % CI 75.1 to
100.0]) aGvHD samples and 49/50 (speciﬁcity 98.0 % [95 % CI
89.3 to 99.7]) control samples of the training set. The subsequent
blinded evaluation on 599 samples collected from 141 patients after
allogeneic HSCT enabled the diagnosis of aGvHD  grade II up
to 14 days prior to clinical symptoms with a sensitivity of 81.4%
[95% CI 73.1 to 87.9]) and a speciﬁcity of 75.7 % [95% CI 71.6 to
79.4].
High resolution proteome analysis may help to identify patients
with aGvHD in an unbiased laboratory based screening, possibly
enabling pre-emptive therapy.
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DIFFERENTIAL IMPACT OF MTOR INHIBITION ON FOXP3 REGULA-
TORY T CELLS AS COMPARED TO CONVENTIONAL T CELLS AFTER
ALLOGENEIC BONE MARROW TRANSPLANTATION
Zeiser, R.1, Leveson-Gower, D.B.1, Zambricki, E.A.1, Hou, J.-Z.1,
Negrin, R.1 1Stanford University School of Medicine, Stanford, CA.
FoxP3CD4CD25 regulatory T-cells (Treg) have been
shown to effectively reduce the severity of experimental acute
graft-versus-host disease (aGvHD) while sparing graft-versus-leu-
kemia activity. These ﬁndings, in concert with the observation that
human and murine Treg share functional characteristics, have
fueled interest in clinical trials to control aGvHD. Recent data
indicates that the immunosuppressant rapamycin (RAPA) in con-
trast to cyclosporine A does not interfere with in vivo function of
Treg and could enhance Treg expansion in vitro by a yet unknown
mechanism. To investigate the impact of mTOR inhibition on
proliferating Treg and Tconv, both cell types were stimulated in
the presence of different RAPA concentrations in vitro. Phosphor-
ylation of mTOR downstream products p70S6K1 and 4E-BP1
were assessed by western blot and ﬂow cytometry. Inhibition of the
phosphorylation of p70S6K1 and 4E-BP1 was observed in both
populations in the presence of RAPA. Interestingly, Treg were
more resistant to mTOR inhibition as compared to Tconv and
displayed signiﬁcantly higher phosphorylated products in the pres-
ence of RAPA at 10 nM (MFI Treg vs Tconv, p0.001) and at
100nM (MFI Treg vs Tconv, p0.001). To investigate whether
Treg and RAPA protect from aGvHD in a synergistic manner,
BALB/c recipients were transplanted with H-2 disparate BM and
1.6106 T-cells (FVB/N) after lethal irradiation. aGvHD lethality
was only slightly reduced when suboptimal Tconv:Treg ratios were
employed, or when recipients were treated with a non-protective
RAPA dose (0.5 mg/kg bodyweight). Combining a suboptimal
Tconv:Treg ratio with a non-protective RAPA dose reduced ex-
pansion of luciferase expressing (luc) Tconv and pro-inﬂamatory
cytokines and improved survival indicative for an additive in vivo
effect of RAPA and Treg. To evaluate the impact of RAPA on in
vivo T cell expansion, either luc Tconv or luc Treg were adot-
ively transferred. In vivo bioluminescence imaging demonstrated
that RAPA had a more potent inhibitory effect on proliferation of
Tconv as compared to Treg (p0.05 vs. NS). We did not observe
RAPA to increase FoxP3Treg numbers in vivo. Thus, increased
Treg numbers observed in RAPA containing expansion cultures
are likely due to a lower susceptibility of this cell population to
mTOR inhibition. This could explain the observed synergistic
effect of RAPA and Treg in aGvHD protection which has rele-
vance for clinical trials utilizing Treg to prevent aGvHD.
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HUMAN LEUKOCYTE ANTIGEN (HLA) HAPLOTYPES AND SINGLE HLA
ANTIGENS IN HLA-MATCHED ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (ALLOHSCT) FOR MYELOID DISEASES: ANAL-
YSIS OF OVERALL AND PROGRESSION FREE SURVIVAL (OS/PFS)
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Donor and recipient mismatching in the HLA system is a major
factor inﬂuencing alloHSCT outcome. There is increasing evidence
that speciﬁc HLA antigens inﬂuence immunobiological outcomes
even in HLA-matched alloHSCT. This could be related to the phys-
iological role of the HLA system in differential antigen presentation.
In contrast, HLA haplotypes are associated with multiple immuno-
pathologic diseases by possible inﬂammatory response modulation in
an antigen-independent manner. We recently reported an association
of HLA haplotypes with acute GvHD. We present results of a ret-
rospective review of 119 related and 48 unrelated consecutive ﬁrst
alloHSCT pts treated at RPCI from 1992 to 2003 to investigate the
association of the 3 most common haplotypes in Caucasians
(A1B8DR3, A3B7DR15 and A2B44DR4) and HLA antigens, in ad-
dition to standard transplant risk factors, onOS and PFS. HLA typing
was determined by either molecular (n108) or serologic (n59)
methods. All analyzed patients were matched at HLA-A, -B and
-DRB1 antigen level. Pt characteristics included: 50% AML, 38%
CML and 12% MDS; median age 43 years (range 11-66), 60% 40
years; 62% Male; 95% Caucasian; 73% Recipient-Donor Sex
Match; 78% TBI-containing conditioning regimens; and 88% bone
marrow stem cell source. There were no signiﬁcant differences in pt
characteristics by the presence or absence of each haplotype or anti-
gen. By univariate analysis, HLA-A24 (p0.047) was signiﬁcantly
associated with improved OS whereas HLA-B8 (p0.034), KPS
80 (p0.0045), 40 yrs (p0.0014), and TBI-containing regi-
mens (p0.016) were associated with decreased OS. HLA haplotype
A1B8DR3 trended towards inferior OS (p0.09). Multivariate anal-
ysis found that HLA-B8, age 40 yrs, KPS80 and TBI-contain-
ing regimens were signiﬁcant independent predictors of decreased
OS. Univariate analysis showed that HLA-B8 (p0.0003), -DR3
(p0.026) and A1B8DR3 (p0.028) were signiﬁcantly associated
with inferior PFS. Multivariate analysis found HLA-B8 was the only
signiﬁcant factor associated with decreased PFS. In Caucasians,
HLA-B8 is rarely seen outside the A1B8DR3 haplotype, therefore it
is not possible to distinguish differential antigen presentation from
non-speciﬁc inﬂammation as underlying immunobiologic mecha-
nisms for the survival differences. Larger patient population analyses
are required to differentiate these mechanisms.
Factors inﬂuencing OS and PFS: Mutivariate Analyses
Significant for inferior OS
Relative
Risk
95% Confidence
Interval
Age > 40 yrs 2.01 1.3-3.2
KPS < 80 1.7 1.1-2.6
TBI based regimen 2.4 1.3-4.4
HLA B8 1.8 1.1-3.0
Significant for inferior PFS
HLA B8 3.6 1.7-7.8
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